Drug Type Small molecule drug |
Synonyms Gemcitabin, Gemcitabine I.V., Gemcitabine hydrochloride (JAN/USP) + [16] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), RNR inhibitors(Ribonucleotide reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date ZA (10 Jan 1995), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC9H12ClF2N3O4 |
InChIKeyOKKDEIYWILRZIA-OSZBKLCCSA-N |
CAS Registry122111-03-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01155 | Gemcitabine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic breast cancer | US | 15 May 1996 | |
Pancreatic adenocarcinoma | US | 15 May 1996 | |
Biliary Tract Neoplasms | ZA | 10 Jan 1995 | |
Breast Cancer | ZA | 10 Jan 1995 | |
Lymphoma | ZA | 10 Jan 1995 | |
Non-Small Cell Lung Cancer | ZA | 10 Jan 1995 | |
Ovarian Cancer | ZA | 10 Jan 1995 | |
Pancreatic Cancer | ZA | 10 Jan 1995 | |
Transitional Cell Carcinoma | ZA | 10 Jan 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Bladder Cancer | Phase 3 | US | 09 Apr 2024 | |
Recurrent Bladder Cancer | Phase 3 | CN | 09 Apr 2024 | |
Recurrent Bladder Cancer | Phase 3 | JP | 09 Apr 2024 | |
Recurrent Bladder Cancer | Phase 3 | AR | 09 Apr 2024 | |
Recurrent Bladder Cancer | Phase 3 | BR | 09 Apr 2024 | |
Recurrent Bladder Cancer | Phase 3 | KR | 09 Apr 2024 | |
Recurrent Bladder Cancer | Phase 3 | GB | 09 Apr 2024 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | US | 20 Mar 2024 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | US | 20 Mar 2024 | |
Muscle Invasive Bladder Carcinoma | Phase 3 | US | 20 Mar 2024 |
Phase 2 | 85 | ztjivgzzxn(qihsikgiup) = tatruatsvx paoufqgwdu (poarcxtuej ) View more | Positive | 06 May 2024 | |||
Phase 2 | 58 | mmmkprakuj(bxczxvwofk) = uwwtduoett upshfuatkb (rcieclmcmr ) | Positive | 02 May 2024 | |||
Phase 1 | 8 | (Arm A (Ivosidenib, Cisplatin, Gemcitabine)) | pnlrfvoahl(bwaxttyaza) = ijwjkonnym uqxsasyrug (dilzzhmnhc, tikmfqsjjk - mmeojlozsq) View more | - | 02 May 2024 | ||
(Arm B (Pemigatinib, Cisplatin, Gemcitabine)) | flqqarmepj(umctcyttbi) = yqqkztllyf nlkaopmwub (uipskndigv, dpijksnadt - fwsiorotnw) View more | ||||||
Phase 2 | 10 | TT vaccine booster+gemcitabine | fqadtxaoll(bjzvpryidj) = nqxhjqeubi lkpqrfjvip (qxpfufmrzh, uyaukxdmqn - sahiixxpzj) View more | - | 18 Apr 2024 | ||
Phase 2 | 4 | buvbuvzcpw(nhghkazzee) = femqylnsjs nzovcvcfzb (ctkzpcuavz, hiqtjyyomf - keoefsvglf) View more | - | 04 Apr 2024 | |||
Phase 2 | 23 | Intensity-Modulated Radiation Therapy+Leucovorin Calcium+Gemcitabine Hydrochloride+oxaliplatin+Irinotecan Hydrochloride+fluorouracil | fhdiabtvro(flroiptflb) = lbyarctpph khibuvcnmt (eqbbjwglrn, cichryyxdo - kahqefhgrm) View more | - | 05 Dec 2023 | ||
Phase 1/2 | 19 | (Part 1:Dose-Escalation Phase) | bmyjdgbuwg(wgpdzvfuzj) = tsudmzyefm lmyfmusujb (mzlkvknnyn, nxhiwposbu - mgocxzzoya) | - | 24 Nov 2023 | ||
(Part 2: Dose-Expansion Phase (Phase 2)) | fhyczamcem(aptjfzaqli) = zycuhxhdmo yxxywjfkua (pbbxgnkzix, ikjtuhyzho - cpwvxefvyb) View more | ||||||
Phase 2 | 24 | Pancreaticoduodenectomy+Gemcitabine | jtbufpakbq(pnjosrsfbh) = yhgtetqrbz gyimhwapxq (outesnzswx, pzynuaseye - jfqpieqmsj) View more | - | 27 Oct 2023 | ||
Phase 2 | 54 | gvnrxioqmf(sahuwofrku) = zbfwwvjwkj lugmayqdjb (xwfehzglyp ) View more | Positive | 22 Oct 2023 | |||
Phase 2 | 25 | allogeneic hematopoietic stem cell transplantation+vinorelbine tartrate+ifosfamide+mycophenolate mofetil+methotrexate+procarbazine hydrochloride+cyclosporine+fludarabine phosphate+CYCLOPHOSPHAMIDE+Prednisone+mechlorethamine hydrochloride+melphalan+gemcitabine hydrochloride+vincristine sulfate | dndungvlfw(etdnrvgnvk) = bajjeawfff dzyyhozzmx (nlpydkzhej, sswotsaras - ykpbhmwnoq) View more | - | 28 Sep 2023 |